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ABSTRACT
Objective: Although multiple noncost factors likely inﬂuence a patient’s
propensity to forego treatment in the face of cost pressures, little is known
about how patients’ sociodemographic characteristics, physical and
behavioral health comorbidities, and prescription regimens inﬂuence cost-
related nonadherence (CRN) to medications. We sought to determine both
ﬁnancial and nonﬁnancial factors associated with CRN in a nationally
representative sample of older adults.
Methods: We used a conceptual model developed by Piette and colleagues
that describes ﬁnancial and nonﬁnancial factors that could increase some-
one’s risk of CRN, including income, comorbidities, and medication
regimen complexity. We used data from the 2004 wave of the Health and
Retirement Study and the 2005 HRS Prescription Drug Study to examine
the inﬂuence of factors within each of these domains on measures of CRN
(including not ﬁlling, stopping, or skipping doses) in a nationally repre-
sentative sample of Americans age 65+ in 2005.
Results: Of the 3071 respondents who met study criteria, 20% reported
some form of CRN in 2005. As in prior studies, indicators of ﬁnancial
stress such as higher out-of-pocket payments for medications and lower
net worth were signiﬁcantly associated with CRN in multivariable analy-
ses. Controlling for these economic pressures, relatively younger respon-
dents (ages 65–74) and depressive symptoms were consistent independent
risk factors for CRN.
Conclusions: Noncost factors inﬂuenced patients’ propensity to forego
treatment even in the context of cost concerns. Future research encom-
passing clinician and health system factors should identify additional
determinants of CRN beyond patients’ cost pressures.
Keywords: cost-related medication nonadherence, depressive symptoms,
ﬁnancial, older adults.
Introduction
Out-of-pocket (OOP) prescription medication costs are increas-
ing for many Americans, and a substantial number of patients
experience cost-related medication nonadherence (CRN) [1–4].
This nonadherence can lead to serious adverse health events
[5–9]. Financial risk factors associated with CRN are well docu-
mented, including low income, lack of drug coverage, and high
copayment burden [8,10–15].
Financial pressures alone, however, explain only a minority of
the variance in patients’ risk for CRN [16], and nonﬁnancial
predictors of patients’ adherence in the context of cost pressures
are poorly understood [6]. Identifying potentially modiﬁable
factors inﬂuencing nonadherence [17] could beneﬁt patient
health and well being by providing clinicians and health systems
information about who might beneﬁt from targeted adherence
counseling or changes in their treatment plan to promote more
effective pharmacotherapy. Most studies that explore predictors
or correlates of CRN are not theoretically grounded [6,18], and
examining a variety of factors simultaneously that have been
shown to be associated with CRN could highlight the relative
importance of various domains such as patients’ ability to pay,
medical comorbidities, and mental health.
The current study takes advantage of a large nationally rep-
resentative sample of older adults to concurrently examine cor-
relates of CRN using a conceptual model developed by Piette
et al. [16], which posits an approach to understanding the inﬂu-
ence of patient, medication, clinician, and health system factors
on individuals’ responses to medication costs [18]. While previ-
ous studies have either explored predictors of CRN [8,10,12–
14,16,19–23] or have reviewed the literature on factors
associated with CRN [6,18], our study is the ﬁrst to apply a
theoretically grounded conceptual model using all of these pre-
dictors simultaneously and to conduct an empirical analysis of
CRN in a national sample. We sought to test each of these
domains concurrently among patients with multiple chronic dis-
eases and diverse sources of medication coverage.
Methods
Study Populations
We used data from the 2004 wave of the Health and Retirement
Study (HRS) as well as data from the 2005 HRS Prescription
Drug Study (PDS). The HRS is a longitudinal study of a nation-
ally representative cohort of older Americans that was designed
to assess the predictors and consequences of transitions out of the
workforce in later life, and it includes detailed questions about
participants’ health insurance including prescription drug cover-
age [24]. The PDS is a subsample of the HRS drawn from
respondents who participated in the HRS in 2004. It was
designed to help track potential changes in prescription medica-
tion utilization among beneﬁciaries as Medicare Part D was
phased in (a second wave of PDS data was collected in 2007 and
is not yet available). To be eligible for inclusion in the present
study, respondents needed to be aged 65 or older in 2005 (e.g.,
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age eligible for Medicare when the PDS data were collected), and
be self-respondents (i.e., they were able to provide responses
without a proxy respondent). Approximately 40% of the 2004
HRS sample was approached for possible inclusion in the PDS
study, which had a response rate of 88%. Out of the 4684 people
who completed the PDS, 3997 were aged 65+, 3394 had data on
CRN, and 3071 responded without a proxy. Therefore, our ﬁnal
study sample size was 3071.
The HRS and PDS provide excellent data for testing our
conceptual model because they include indicators of several of
the posited domains, including indicators of ﬁnancial pressures
for CRN (income, insurance coverage, and number of prescrip-
tions), as well as nonﬁnancial factors that could mitigate or
exacerbate patients’ risk of CRN: patient sociodemographic
characteristics, health status indicators, and medication charac-
teristics. Less information is included in these datasets regarding
other domains described in the conceptual model such as clini-
cian counseling and health system characteristics [6,18]. Vari-
ables from the PDS included: CRN, OOP medication costs, drug
coverage, adverse medication effects, number of monthly pre-
scriptions, and age. All other variables were taken from the HRS.
These variables are included in a modiﬁcation of Piette et al.’s
[16] conceptual model in Figure 1.
All analyses were weighted and adjusted for HRS’ complex
sampling design (stratiﬁcation and clustering) and used SAS 9.2
(SAS Institute, Cary, NC). The Institutional Review Board of the
University of Michigan Medical School approved this research
project and it received exempt status.
Dependent Variable
Participants were considered to have experienced CRN if they
reported any of the following behaviors during the past year: 1)
not ﬁlling a new prescription because of cost; 2) stopping taking
a medication because of cost; or 3) skipping doses of a medica-
tion to save money. This study used similar measures to other
studies of CRN [25], and other studies have used a similar
approach to group CRN behaviors to create a global measure of
“any CRN” [11,13]. In auxiliary analyses, we also examined
each CRNmeasure separately and found similar but not identical
results. Therefore, we present results using both the “any CRN”
measure and each individual CRN item as outcomes.
Independent Variables
We chose independent variables based on data from the HRS and
PDS that were in accordance with the domains of our conceptual
model:
Measures of ﬁnancial pressures included out-of-pocket
expenditures (measured in quartiles: $0 to $20, $20.01 to $50,
$50.01 to $110, >$110) for a month supply of “regular” drugs,
other OOP medical expenses from the previous 2-year period
(measured in quartiles: $0 to $580, $580.01 to $1792.50,
$1792.51 to $4570, >$4570), net worth (measured in quartiles:
$0 to $38,000, $38,000.01 to $154,500, $154,500.01 to
$425,000, >$425,000), annual household income (measured in
quartiles: $0 to $14,042.11, $14,042.12 to $25,660, $25,660.01
to $48,384, >$48,384), and any drug coverage (yes or no and
including employer, private purchase, Medicaid, VA, Medicare
HMO or Medicare + Choice plan, or state pharmacy assistance
program).
Demographic characteristics included age (65–74, 74–85,
85+), education (high school graduate or less, at least some
college), sex, employment status (working, not working, retired),
current marital status (married, separated/divorced, widowed,
never married), and race/ethnicity (white, black, Hispanic, other).
Figure 1 Conceptual framework for the factors inﬂuencing patients’ risk of cost-related nonadherence (adapted from Piette et al. [18]).
ADL, activities of daily living; IADL, instrumental activities of daily living.
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Patients’ burden of chronic illness was measured using indi-
cators for each of eight chronic medical conditions: 1) high blood
pressure or hypertension; 2) diabetes or high blood sugar; 3)
cancer or a malignant tumor of any kind except skin cancer; 4)
chronic lung disease except asthma such as chronic bronchitis or
emphysema; 5) heart attack, coronary heart disease, angina,
congestive heart failure, or other heart problems; 6) stroke or
transient ischemic attack; 7) emotional, nervous, or psychiatric
problems; and 8) arthritis or rheumatism. Other health-related
characteristics included patients’ perception of their overall
health (excellent vs. very good, good, fair, or poor), limitations in
each of ﬁve activities of daily living (eating, getting in and out of
bed, dressing, bathing, and walking across a room, measured as
0 vs. 1) and ﬁve instrumental activities of daily living (prepar-
ing meals, grocery shopping, making phone calls, taking medi-
cations, and managing money measured as 0 vs. 1) [26].
To determine depressive symptoms, each respondent was
asked the following eight depressive symptoms questions taken
from the Center for Epidemiologic Studies Depression (CES-D)
scale [27,28] (with response options of “yes” or “no”): 1) Much
of the time during the past week, I felt depressed; 2) I felt
everything I did was an effort; 3) My sleep was restless; 4) I was
happy; 5) I felt lonely; 6) I enjoyed life; 7) I felt sad; and 8) I could
not “get going.” The total number of “yes” responses to ques-
tions 1, 2, 3, 5, 7, 8, and the “no” responses to questions 4 and
6 were summed to arrive at a total depressive symptom score that
ranged from 0 to 8, which has been shown to have a Cronbach’s
alpha of >0.8 in the HRS data [28]. In our multivariable models,
we used a three-level aggregated measure of CES-D scores of 0
(no symptoms), 1–3 (depressive symptoms), and 4 (depressed).
This cut point of 4 has been found to produce comparable
results to the 16-symptom cutoff for the well-validated 20-item
CES-D scale [28].
Prescription regimen characteristics included the number of
different prescriptions a respondent reported using in the last
month (0–2, 3–4, 5–6, 7). Patients also reported whether they
experienced any adverse effects associated with medication use
(yes or no).
An additional variable was used from the clinician factors
domain from the theoretical model. This question asked respon-
dents who they trust to make decisions about health insurance
and response choices included family members (spouse, child,
other), friends, ﬁnancial advisors, as well as doctors, nurses or
other health-care providers (measured as no one, family/friend,
or professional).
Analytic Framework
Weused chi-square tests for categorical or dichotomousmeasures,
to determine the bivariate association between respondent char-
acteristics and CRN. Next, we used logistic regression analysis to
identify which factors inﬂuenced whether a respondent experi-
enced CRN in unadjusted and adjusted analyses. Predictors that
had a P-value of 0.2 in unadjusted analyses were considered as
candidate predictors in our full model. We removed predictors
from the full model that were no longer signiﬁcant at the P < 0.05
level (e.g., the backward elimination regression analysis proce-
dure) to arrive at our ﬁnal model. To further test the robustness of
our ﬁndings, we conducted several adjusted logistic regression
analyses (all using backward elimination regression analysis).
First, we examined “any CRN” (i.e., not ﬁlling, stopping, or
skipping as deﬁned above) as an outcome variable. Second, we
examined each of the three individual CRN items as a separate
outcome variable. Finally, we conducted a subgroup analysis in
which we only examined “any CRN” among low income respon-
dents with high OOP payments for medications (deﬁned as below
median income and above median OOP payments for medica-
tions). All analyses were conducted using SAS 9.2 and were
weighted and adjusted for the complex sampling design (stratiﬁ-
cation and clustering) of the HRS and PDS in order to achieve
estimates reﬂective of the US population 65 years of age.
Results
There were several factors associated with CRN in bivariate
analyses, as shown in Table 1. Of note, respondents experiencing
CRN had higher OOP costs per month, lower net worth, had
lower household income, were less likely to have prescription
drug coverage, were younger, were more often female, had more
chronic conditions, had lower self rated health, had more func-
tional limitations, reported greater levels of depressive symp-
toms, and were more likely to report adverse effects of
medication treatment, than those not experiencing CRN.
Table 2 illustrates the results from multivariable logistic
regression analyses. Since respondents’ job status, heart prob-
lems, diabetes, and cancer were no longer signiﬁcant independent
predictors in the context of other covariates, they were dropped
from the ﬁnal model. Of the remaining candidate predictors,
several nonﬁnancial factors were found to be independently asso-
ciated with CRN controlling for respondents’ OOP prescription
costs, household income, prescription medication coverage, and
net worth. In particular, more depressive symptoms had a strong
independent association with CRN (compared to no depression
symptoms, odds ratio (OR)1–3 symptoms 1.59; 95% conﬁdence inter-
val (CI) 1.21, 2.08; OR4–8 symptoms 2.23; 95% CI 1.56, 3.18).
Women were more likely than men to experience CRN (OR 1.62;
95% CI 1.23, 2.13). Respondents who were younger were more
likely to experience CRN (compared to respondents aged 65–74,
OR75–84 0.74; 95% CI 0.57, 0.98; OR85+ 0.49; 95% CI 0.26,
0.63). Finally, hypertension was independently associated with
lower rates of CRN (OR 0.74; 95% CI 0.56, 0.98), whereas lung
disease was associated with higher rates of CRN (OR 1.50; 95%
CI 1.12, 2.02). We found no evidence of lack of ﬁt in our ﬁnal
model (assessed using the Hosmer-Lemeshow goodness-of-ﬁt test
[29], which was equal to 0.49) and we used Nagelkerke’s r2 to
examine the model ﬁt (given that our outcome variable was
dichotomous), which was equal to 0.20 [30].
Table 3 replicates results from Table 2 indicating our ﬁndings
from our trimmed multivariable model after backward elimina-
tion of nonsigniﬁcant terms predicting “any CRN.” In addition,
we present ﬁndings from analyses of each individual CRN item.
While there were some individual differences among items that
were associated with CRN, consistent predictors of CRN
included OOP per month for prescription medications, lower net
worth, younger–old age (65–74), and depressive symptoms.
Finally, in our analyses of the subgroup of the most vulner-
able respondents (low income and high OOP), we found remark-
ably similar predictors of any CRN: highest quartile of OOP per
month for prescription medications, lower net worth, age < 85,
depressive symptoms, female gender, nonhypertensive, and
adverse effects of medication use.
Discussion
Although our study differed from past studies by simulta-
neously considering many ﬁnancial, socioeconomic, and health
factors, our results were similar to the ﬁndings of previous
studies that considered only limited subsets of these factors
[6,10,11,14,23,31]. We found the main drivers of CRN to be
associated with patients’ ability to pay for their medications,
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Table 1 Baseline predictors of CRN
No CRN CRN
P-value
N = 2457 N = 614
N % N %
Financial characteristics
OOP Rx cost per month $0.00–$20.00 610 29.99 86 16.20 <0.0001
$20.01–$50.00 533 26.20 98 18.46
$50.01–$110.00 479 23.55 142 26.74
$110.01 412 20.26 205 38.61
Other OOP medical costs $0.00–$580.00 630 25.64 121 19.71 <0.0001
$580.01–$1,792.50 646 26.29 139 22.64
$1,792.51–$4,570.00 644 26.21 153 24.92
$4,570.01 537 21.86 201 32.74
Net worth $38,000.00 516 21.00 201 32.74 <0.0001
$38,000.01–$154,500.00 583 23.73 195 31.76
$154,500.01–$425,000.00 640 26.05 141 22.96
$425,000.01 718 29.22 77 12.54
Total household income $0–$14,042.11 531 21.63 178 29.18 <0.0001
$14,042.12–$25,660.00 580 23.63 193 31.64
$25,660.01–$48,384.00 641 26.11 149 24.43
$48,384.01 703 28.64 90 14.75
Prescription drug coverage No 527 21.45 192 31.27 <0.0001
Yes 1,930 78.55 422 68.73
Demographic characteristics
Age 65–74 1,303 53.03 384 62.54 <0.0001
75–84 835 33.98 183 29.80
85 319 12.98 47 7.65
Gender Female 1,423 57.92 442 71.99 <0.0001
Male 1,034 42.08 172 28.01
Education High school grad or less 1,537 62.58 467 76.18 <0.0001
At least some college 919 37.42 146 23.82
Job status Working 256 10.42 54 8.79 0.4896
Not working 283 11.52 72 11.73
Retired 1,918 78.06 488 79.48
Marital status Married 1,481 60.30 323 52.61 0.0005
Separated/divorced 218 8.88 68 11.07
Widowed 695 28.30 201 32.74
Never married 62 2.52 22 3.58
Race White 2,075 84.45 482 78.50 0.0002
Black 292 11.88 111 18.08
Hispanic 39 1.59 14 2.28
Other 51 2.08 7 1.14
Lives alone No 1,766 71.88 425 69.22 0.1926
Yes 691 28.12 189 30.78
Child lives within 10 miles No 1,483 60.36 334 54.40 0.0072
Yes 974 39.64 280 45.60
Disease characteristics
Ever had high blood pressure No 906 36.90 204 33.22 0.0897
Yes 1,549 63.10 410 66.78
Ever had lung disease No 2,231 90.84 512 83.39 <0.0001
Yes 225 9.16 102 16.61
Ever had stroke No 2,222 90.51 561 91.37 0.5126
Yes 233 9.49 53 8.63
Ever had arthritis No 790 32.21 139 22.71 <0.0001
Yes 1,663 67.79 473 77.29
Ever had a psychiatric disorder No 2,133 86.92 475 77.36 <0.0001
Yes 321 13.08 139 22.64
Ever had heart problems No 1,702 69.38 418 68.19 0.5666
Yes 751 30.62 195 31.81
Ever had diabetes No 1,951 79.57 467 76.18 0.0662
Yes 501 20.43 146 23.82
Ever had cancer No 2,034 82.99 520 84.97 0.2390
Yes 417 17.01 92 15.03
Self-rated health Excellent 228 9.29 28 4.56 <0.0001
Very good 680 27.70 118 19.22
Good 853 34.75 199 32.41
Fair 524 21.34 191 31.11
Poor 170 6.92 78 12.70
ADLs 0 2,069 84.21 469 76.38 <0.0001
1 388 15.79 145 23.62
IADLs 0 2,100 85.47 492 80.13 0.0011
1 357 14.53 122 19.87
CES-D score 0 1,124 45.86 159 25.90 <0.0001
1–3 996 40.64 299 48.70
4 331 13.50 156 25.41
Cognitive impairment No 2,336 95.27 585 95.28 0.9936
Yes 116 4.73 29 4.72
Regimen complexity
# of monthly prescriptions 0–2 649 27.79 119 20.24 0.0001
3–4 716 30.66 172 29.25
5–6 468 20.04 132 22.45
7 502 21.50 165 28.06
Medication characteristics
Adverse events No 2,102 85.55 451 73.45 <0.0001
Yes 355 14.45 163 26.55
Clinician characteristics
Trust for insurance decisions No one 473 19.78 85 14.31 0.0031
Family/friend 1,596 66.75 437 73.57
Professional 322 13.47 72 12.12
ADL, activities of daily living; CES-D, Center for Epidemiologic Studies Depression Scale; CRN, cost-related nonadherence; IADL, instrumental ADL; OOP, out-of-pocket.
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particularly among those with low income and high OOP drug
costs. Nevertheless, we also found that in addition to sociode-
mographic correlates of CRN (such as younger age and female
gender) some potentially modiﬁable predictors of CRN include
comorbid illness such as depression.
This study replicates ﬁndings from other studies indicating
that depression is signiﬁcantly associated with CRN [19,32],
independent of patients’ ability to pay. In fact, the current study
indicates that depression is the strongest correlate of CRN once
ﬁnancial pressures have been taken into account. In other words,
this association cannot be explained by lack of drug coverage,
poverty, or higher OOP among more depressed respondents [6],
because the relationship was maintained even when we con-
trolled for these and other potential confounders.
Although chronic health conditions such as diabetes are
usually associated with CRN [31], even when controlling for
Table 2 Unadjusted and adjusted predictors of cost-related nonadherence
Unadjusted models* Full model† Final model‡
OR 95% CI OR 95% CI OR 95% CI
Financial characteristics
OOP Rx cost per month (reference is $0.00–$20.00) $20.01–$50.00 1.45 1.07–1.96 1.56 1.12–2.17 1.61 1.16–2.22
$50.01–$110.00 2.28 1.57–3.30 2.29 1.42–3.70 2.40 1.61–3.58
$110.01 4.13 3.09–5.53 4.38 2.95–6.50 4.74 3.56–6.30
Other OOP medical costs (reference is $0.00–$580.00) $580.01–$1,792.50 1.04 0.77–1.39 1.07 0.74–1.55
$1,792.51–$4,570.00 1.27 0.97–1.67 1.05 0.74–1.50
$4,570.01 2.03 1.50–2.75 1.16 0.75–1.80
Net worth (reference is $38,000.00) $38,000.01–$154,500.00 0.89 0.67–1.18 0.88 0.64–1.21 0.80 0.58–1.09
$154,500.01–$425,000.00 0.56 0.43–0.73 0.60 0.42–0.88 0.52 0.37–0.72
$425,000.01 0.30 0.21–0.43 0.40 0.26–0.59 0.28 0.18–0.43
Total household income (reference is $0.00–$14,042.11) $14,042.12–$25,660.00 0.97 0.73–1.28 0.97 0.67–1.40
$25,660.01–$48,384.00 0.69 0.52–0.90 0.92 0.63–1.33
$48,384.01 0.42 0.28–0.62 0.65 0.40–1.06
Any drug coverage (reference is no) Yes 0.59 0.44–0.79 0.77 0.54–1.09
Demographic characteristics
Age (reference is 65–74) 75–84 0.80 0.61–1.04 0.69 0.51–0.94 0.71 0.54–0.94
85 0.52 0.35–0.77 0.36 0.21–0.63 0.38 0.25–0.58
Gender (reference is male) Female 1.86 1.50–2.30 1.47 1.12–1.94 1.51 1.16–1.96
Education (reference is high school grad or less) At least some college 0.59 0.49–0.71 0.86 0.67–1.12
Job status (reference is working) Not working 1.10 0.72–1.69
Retired 1.06 0.74–1.51
Marital status (reference is married) Never married 1.68 1.00–2.82 1.80 0.97–3.36
Separated/divorced 1.37 1.05–1.78 1.16 0.66–2.03
Widowed 1.37 1.07–1.76 1.07 0.73–1.58
Race (reference is white) Black 1.71 1.24–2.36 1.15 0.76–1.73
Hispanic 1.78 0.79–4.01 0.67 0.17–2.60
Other 0.50 0.22–1.14 0.53 0.23–1.22
Lives alone (reference is no) Yes 1.19 0.96–1.47 0.83 0.56–1.23
Child lives within 10 miles (reference is no) Yes 1.24 1.00–1.54 1.06 0.83–1.35
Disease characteristics
Ever had high blood pressure (reference is no) Yes 1.18 0.93–1.50 0.73 0.55–0.98 0.75 0.57–0.98
Ever had lung disease (reference is no) Yes 2.03 1.50–2.74 1.51 1.08–2.12 1.48 1.10–1.98
Ever had stroke (reference is no) Yes 0.86 0.63–1.18
Ever had arthritis (reference is no) Yes 1.67 1.33–2.11 1.19 0.85–1.68
Ever had a psych disorder (reference is no) Yes 2.03 1.59–2.59 1.10 0.78–1.53
Ever had heart problems (reference is no) Yes 1.01 0.83–1.23
Ever had diabetes (reference is no) Yes 1.13 0.91–1.40
Ever had cancer (reference is no) Yes 0.93 0.70–1.25
Self-rated health (reference is poor) Excellent 0.31 0.18–0.53 1.28 0.58–2.82
Very good 0.37 0.26–0.54 1.08 0.63–1.84
Good 0.52 0.37–0.74 1.08 0.65–1.77
Fair 0.79 0.55–1.14 1.18 0.71–1.96
ADLs (reference is 0) 1 1.58 1.29–1.93 0.96 0.65–1.42
IADLs (reference is 0) 1 1.46 1.11–1.92 1.01 0.71–1.44
CES-D score (reference is 0) 1–3 1.81 1.38–2.38 1.53 1.13–2.07 1.64 1.25–2.14
4 2.96 2.28–3.84 2.09 1.38–3.17 2.25 1.59–3.20
Cognitive impairment (reference is no) Yes 1.15 0.72–1.84
Regimen complexity
# of monthly prescriptions (reference is 0–2) 3–4 1.49 1.13–1.97 1.06 0.73–1.54
5–6 1.60 1.07–2.40 0.85 0.51–1.40
7 1.91 1.34–2.71 0.83 0.53–1.30
Medication characteristics
Adverse events (reference is no) Yes 2.19 1.77–2.71 1.87 1.43–2.45 1.75 1.36–2.24
Clinician characteristics
Trust for insurance decisions (reference is no one) Family/friend 1.44 1.11–1.86 1.37 0.99–1.91
Professional 1.21 0.80–1.83 1.41 0.89–2.24
Nagelkerke’s R2 –– 0.22 0.20
Hosmer-Lemeshow goodness-of-ﬁt test –– 0.94 0.49
*Goodness-of-ﬁt test statistics and R2 are not available for unadjusted models.
†Covariates were considered for the full model if they had a P-value of 0.2 or less in its unadjusted model.
‡The ﬁnal model was derived using backward elimination on the full model with P-value cutoff of 0.05.
ADL, activities of daily living; CES-D, Center for Epidemiologic Studies Depression Scale; CI, conﬁdence interval; IADL, instrumental activities of daily living; OOP, out-of-pocket, OR, odds ratio.
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depression [19], we did not ﬁnd an association between diabetes,
cancer, stroke, arthritis, or heart disease and CRN. While we do
not know of any prior literature documenting the relationship
between lung disease and CRN directly, one study demonstrated
signiﬁcantly higher rates of lung disease among depressed Medi-
care beneﬁciaries than among nondepressed Medicare beneﬁcia-
ries, where depressed beneﬁciaries experienced signiﬁcantly
higher rates of CRN than their nondepressed counterparts [19].
Given the importance of medications for prevention of disease
progression and adverse disease outcomes for lung disease such
as asthma and chronic obstructive pulmonary disease, it will be
important to further investigate reasons for these observed high
rates of CRN among older adults with lung disease. In contrast,
our study found that hypertension was associated with lower
rates of CRN. While the explanation for this relationship is
unclear, the association is consistent with another study demon-
strating that patients may forego other medications due to
CRN before antihypertensives, perhaps motivated by the life-
threatening nature of hypertension [16]. We note as well that it
may be difﬁcult to interpret the meaning of individual chronic
disease predictors in the absence of additional information about
patient health-related quality of life or life expectancy [18].
While sex is not usually found to be a signiﬁcant predictor of
CRN [6], the current study as well as a few other studies have
found that women are more likely to experience CRN [12,33]. In
order to better understand possible mechanisms for these gender
effects, we examined potential interactions between sex and indi-
cators of respondents’ ﬁnancial status. None of these interactions
was signiﬁcant and more research is needed to determine the
conditions under which women may be more likely than men to
forego their medication due to ﬁnancial pressures.
We note that several of our measures of patients’ ﬁnancial
burden that were signiﬁcant in bivariate analyses were not sig-
niﬁcant predictors of CRN in the ﬁnal model, including drug
coverage, OOP for other medical costs, and household income.
We suspect that OOP for medications would have already
accounted for drug coverage (as OOP is the remainder that a
patient would pay after any drug coverage has kicked in), that
other medical costs are not as strong of a predictor of CRN in the
presence of OOP for prescription medications, and that net
worth and household income are too highly correlated for both
of them to be signiﬁcant predictors of CRN, with net worth being
a better indicator of overall ability to afford items such as
medications.
Adverse events associated with medication use also appeared
to be associated with higher odds of CRN. It makes sense that
adverse effects might provide patients with an incentive to dis-
continue medication use when they are faced with relatively high
or increasing medications costs. Given this, it may be important
for providers to discuss potential adverse effects of medications
with their patients and make modiﬁcations to patients’ medica-
tion regimens as soon as possible to mitigate the negative impact
of adverse events as well as increase patient adherence and well
being.
Some of the strengths of the current study include its use of a
large nationally representative sample of older adults and its
ability to examine multiple possible domains of predictors simul-
taneously. Nevertheless, despite the wealth of data available for
our analyses, there are some limitations. We did not have infor-
mation on a variety of patient level factors including patient
preferences for or beliefs about medication treatment that could
inﬂuence adherence to medication and potentially CRN [34]. We
also could not measure variation in CRN across treatments in the
patients’ regimen. Prior studies suggest that patients may respond
differently when facing costs for essential versus nonessential
treatments or treatments that vary in their importance for lon-
gevity and symptom relief [16,23]. Our analyses suggest that
much of the variance in patient CRN remains unexplained.
In addition, we did not have information on factors related to
the patient–physician relationship including more details about
physician trust [10,32] and communication about costs [22,35],
which may be important inﬂuences on adherence and CRN.
Patients and providers may have different treatment objectives
and goals [36], and may have different ideas about the balance
Table 3 Adjusted predictors of “any CRN” as well as predictors of individual CRN items
Any Not ﬁll Stop taking Skip doses
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Financial characteristics
OOP Rx cost per month (reference is
$0.00–$20.00)
$20.01–$50.00 1.61 1.16–2.22 1.34 0.87–2.05 1.30 0.80–2.12 2.70 1.75–4.16
$50.01–$110.00 2.40 1.61–3.58 1.92 1.20–3.07 2.48 1.50–4.11 3.05 1.89–4.93
$110.01 4.74 3.56–6.30 3.06 2.03–4.62 3.55 2.26–5.59 8.37 5.38–13.04
Net worth (reference is $38,000.00) $38,000.01–$154,500.00 0.80 0.58–1.09 0.82 0.60–1.14 0.86 0.55–1.35 0.73 0.51–1.05
$154,500.01–$425,000.00 0.52 0.37–0.72 0.54 0.37–0.80 0.51 0.34–0.77 0.46 0.30–0.71
$425,000.01 0.28 0.18–0.43 0.26 0.15–0.45 0.29 0.15–0.56 0.45 0.29–0.70





Any drug coverage (reference is no) Yes 0.64 0.48–0.85 0.55 0.39–0.78
Demographic characteristics
Age (reference is 65–74) 75–84 0.71 0.54–0.94 0.69 0.51–0.94 0.63 0.45–0.87 0.67 0.51–0.89
85 0.38 0.25–0.58 0.38 0.25–0.58 0.48 0.31–0.74 0.35 0.20–0.59
Gender (reference is male) Female 1.51 1.16–1.96 1.44 1.08–1.93
Disease characteristics
Ever had high blood pressure (reference is no) Yes 0.75 0.57–0.98
Ever had lung disease (reference is no) Yes 1.48 1.10–1.98 1.56 1.10–2.22
Ever had cancer (reference is no) Yes 0.59 0.39–0.90
CES-D score (reference is 0) 1–3 1.64 1.25–2.14 2.31 1.78–3.00 2.19 1.48–3.26 1.59 1.14–2.21
4 2.25 1.59–3.20 3.21 2.29–4.49 2.79 1.85–4.20 2.27 1.49–3.48
Medication characteristics
Adverse events (reference is no) Yes 1.75 1.36–2.24 2.27 1.75–2.94 2.96 2.10–4.17
Nagelkerke’s R2 0.20 0.21 0.20 0.15
Hosmer-Lemeshow goodness-of-ﬁt test 0.49 0.52 0.68 0.47
CES-D, Center for Epidemiologic Studies Depression Scale; CI, conﬁdence interval; CRN, cost-related nonadherence; OOP, out-of-pocket; OR, odds ratio.
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between necessity and risks associated with medication use that
could also inﬂuence adherence and CRN. Perceived importance
inﬂuences perceived worth and thereby adherence, especially
among high cost drugs [37]. Therefore, future studies should seek
to examine these facets of the patient–provider dynamic concur-
rently with the patient level factors examined in the present
study.
There are some additional limitations associated with our
depression and chronic disease measurement in this study.
Patients’ burden of chronic disease was measured in 2004 and
CRN was measured in 2005. It is possible that disorders, par-
ticularly depression, can be transient. Nevertheless, conversely,
the analyses are largely cross sectional, and future research
should examine the relationship between disease (and other
factors) and CRN over time. Furthermore, variation in CRN by
particular chronic medication conditions may be difﬁcult to inter-
pret, as they may be proxies for other unmeasured patient char-
acteristics such as self efﬁcacy.
Our analyses are also based on self-reported survey measures,
and there may be gaps in respondent knowledge, as research
indicates that people may not be fully aware of their drug cov-
erage and cost-sharing arrangements [23,25,38], which could
also inﬂuence reports of CRN. These analyses were also limited
to older adults (65+) yet we found that the youngest members of
our study experienced the highest levels of CRN. It is possible
that including data from even younger respondents (say middle-
aged adults who were not yet Medicare eligible) would reveal
even higher rates of CRN than in the study sample. Prior studies
suggest that this would be the case [23,34].
Conclusions
Despite these limitations, this research has generated important
conceptually and empirically tested ﬁndings regarding which
factors most strongly inﬂuence CRN. Some of the factors iden-
tiﬁed as predictors of CRN are not modiﬁable (e.g., age and
gender), but should be considered risk factors, thereby poten-
tially requiring additional screening for CRN. Factors that may
be modiﬁable, with varying degrees of difﬁculty, include decreas-
ing levels of depression and lung disease, decreasing OOP expen-
ditures for medications, and even net worth (which could be
slightly modiﬁable depending on the availability of government
programs that could inﬂuence wealth redistribution). Treating
depression may involve incurring additional costs (particularly if
treated with medications). Thus, while an important target for
improving CRN would be to expand medication coverage,
thereby decreasing OOP expenditures associated with prescrip-
tion drugs, other factors clearly also affect CRN besides costs and
coverage. For example, learning more about why some patients
with hypertension appear to have lower rates of CRN could be
instructive, and identiﬁcation of other presently unmeasured
factors like coping skills could allow clinicians and health edu-
cators to address these issues, decreasing rates of CRN even
when costs themselves cannot be reduced. Researchers should
examine the inﬂuences of changes in drug coverage on CRN over
time, as it is known that there is a negative impact of caps on
consumption and outcomes [9], and there is evidence to indicate
that broader coverage may improve outcomes [39]. In particular,
we should measure whether Medicare Part D successfully
decreases CRN for older adults when it is examined in a com-
prehensive context such as the model tested here.
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